![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Judge Strikes $235 Million Patent Infringement Verdict Against Teva
Judge Strikes $235 Million Patent Infringement Verdict Against Teva
![PatentsTabLabel.gif](https://www.fdanews.com/ext/resources/test/Drug-Images4/PatentsTabLabel.gif?t=1579739301&width=430)
March 30, 2018
A Delaware judge threw out a 2017 decision that had Teva on the hook for more than $235 million over its generic for GlaxoSmithKline’s chronic heart failure and blood pressure drug Coreg (carvedilol).
In a decision last June, a federal jury in Delaware found Teva infringed on GSK’s patent for the drug and awarded GSK $234.1 million for lost profits and an additional $1.4 million in royalties.
The FDA approved Teva’s generic in 2004 as a conditional “carve-out” approval, with GSK retaining exclusive rights to market the drug for chronic heart failure. GSK sued when Teva added that indication to its generic’s labeling in 2011.
Upcoming Events
-
21Oct